BRIEF published on 04/16/2024 at 13:05, 2 years 3 months ago CureVac et MD Anderson collaborent sur des vaccins innovants contre le cancer Technologie ARNm CureVac MD Anderson Vaccins Contre Le Cancer Collaboration Biopharmaceutique
PRESS RELEASE published on 04/16/2024 at 13:00, 2 years 3 months ago CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines CureVac and MD Anderson announce strategic collaboration to develop mRNA-based cancer vaccines, leveraging respective expertise to address unmet medical needs in hematological and solid tumors Clinical Research Collaboration CureVac MD Anderson MRNA-based Cancer Vaccines
BRIEF published on 04/04/2024 at 13:05, 2 years 4 months ago CureVac Reports Positive Phase 2 Results for Influenza Vaccine in Collaboration with GSK GSK MRNA Technology CureVac Influenza Vaccine Phase 2 Trial
BRIEF published on 04/04/2024 at 13:05, 2 years 4 months ago CureVac annonce des résultats positifs de phase 2 pour son vaccin contre la grippe en collaboration avec GSK GSK Technologie ARNm CureVac Vaccin Contre La Grippe Essai De Phase 2
PRESS RELEASE published on 04/04/2024 at 13:00, 2 years 4 months ago CureVac Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK CureVac announces positive Phase 2 interim results for seasonal influenza vaccine in collaboration with GSK, showing strong antibody titers and safety profile GSK CureVac Phase 2 Seasonal Influenza Vaccine MRNA
PRESS RELEASE published on 11/01/2023 at 13:00, 2 years 9 months ago CureVac Announces Solid Progress in Phase 2 COVID-19 and Seasonal Flu Clinical Development Programs in Collaboration with GSK
PRESS RELEASE published on 09/28/2023 at 13:00, 2 years 10 months ago CureVac Reports Progress in Intellectual Property Infringement Case Against BioNTech in Germany
PRESS RELEASE published on 09/12/2023 at 13:15, 2 years 10 months ago CureVac Advances Seasonal Flu Study to Phase 2 in Collaboration with GSK Following Selection of Promising mRNA Vaccine Candidate with Broad Coverage
PRESS RELEASE published on 09/12/2023 at 13:00, 2 years 10 months ago CureVac Advances Seasonal Flu Study to Phase 2 in Collaboration with GSK Following Selection of Promising mRNA Vaccine Candidate with Broad Coverage
PRESS RELEASE published on 08/17/2023 at 13:00, 2 years 11 months ago CureVac Announces Financial Results for the Second Quarter and First Half of 2023 and Provides Business Update
Published on 08/06/2026 at 15:00, 1 hour 33 minutes ago Norsemont Strategically Expands Choquelimpie Land Package To 9,048 Hectares
Published on 08/06/2026 at 14:30, 2 hours 3 minutes ago Loar Holdings Inc. Reports Q2 2026 Record Results and Upward Revision to 2026 Outlook
Published on 08/06/2026 at 14:30, 2 hours 3 minutes ago NV Gold Announces Expansion of Holdings and Drill Program at the Slumber Gold Project in Nevada
Published on 08/06/2026 at 14:30, 2 hours 3 minutes ago AIAI Holdings' MediGuide Launches Longevity Intelligence, Redefining Personalized Preventive Healthcare
Published on 08/06/2026 at 14:00, 2 hours 33 minutes ago Adcore to Publish Second Quarter 2026 Results on August 13, 2026
Published on 08/06/2026 at 16:15, 18 minutes ago Monotype and Kittl Expand Partnership To Bring Brand Typography Directly Into Creative Workflows
Published on 08/06/2026 at 15:20, 1 hour 13 minutes ago Form 8.3 - The Vanguard Group, Inc.: SEGRO plc
Published on 08/06/2026 at 15:19, 1 hour 13 minutes ago Form 8.3 - The Vanguard Group, Inc.: Schroders plc
Published on 08/06/2026 at 15:19, 1 hour 14 minutes ago Form 8.3 - The Vanguard Group, Inc.: Prologis, Inc.
Published on 08/06/2026 at 15:18, 1 hour 15 minutes ago Form 8.3 - The Vanguard Group, Inc.: Picton Property Income Limited
Published on 08/06/2026 at 08:44, 7 hours 48 minutes ago IDI annonce la cession du groupe Talis à son fondateur, Serge Marcillaud, accompagné de l'équipe dirigeante
Published on 08/06/2026 at 08:00, 8 hours 33 minutes ago EURAZEO ENTRE EN DISCUSSIONS EXCLUSIVES AVEC PARTNERS GROUP EN VUE DE LA CESSION DE SA PARTICIPATION DANS AROMA-ZONE ET DE SON RÉINVESTISSEMENT À SES CÔTÉS
Published on 08/06/2026 at 08:00, 8 hours 33 minutes ago EURAZEO ENTERS INTO EXCLUSIVE DISCUSSIONS WITH PARTNERS GROUP REGARDING THE CONTEMPLATED SALE OF ITS STAKE IN AROMA-ZONE AND ITS REINVESTMENT
Published on 08/06/2026 at 07:48, 8 hours 44 minutes ago ENGIE - Déclaration du nombre total d'actions et de droits de vote au 31 juillet 2026
Published on 08/05/2026 at 18:00, 22 hours 33 minutes ago Informations relatives au nombre total de droits de vote et d’actions composant le capital social au 31 juillet 2026
